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The specificity of a sandwich enzyme-linked immunosorbent assay (ELISA) for detecting Aspergillus galac­
tomannan was tested with exoantigens of 29 fungi cultured from clinical specimens. Cross-reactivity was 
observed with Pénicillium chrysogenum, Pénicillium digitatum, and Paecilomyces variotii. Furthermore, 40 serum 
samples obtained from bacteremic patients with hematologic malignancies were retrospectively tested by 
sandwich ELISA. False-positive reactions with the serum were reproducible but did not correspond with the 
results of culture of specific microorganisms. Moreover, the microorganisms cultured from the blood showed 
no reactivity by the sandwich ELISA.
Invasive aspergillosis is an opportunistic fungal infection 
which primarily affects the lungs, Among the patient popula­
tions at greatest risk for infection are those with inadequate 
numbers of circulating neutrophils and those with defective 
neutrophil function. The crude mortality for patients with in­
vasive aspergillosis is up to 95% (4), which is partly due to the 
difficulty of diagnosing the infection at an early stage of dis­
ease. Definitive evidence of infection can be obtained only by 
demonstrating invasive growth of hyphae in tissue and culture 
of Aspergillus species from the same tissue specimen. However, 
the presence of severe thrombocytopenia often precludes the 
possibility of obtaining a specimen by invasive procedures. 
Therefore, a multidisciplinary approach is required, in which 
the results of clinical, radiological, and microbiological exam­
inations are combined. The detection of fungal antigens in 
serum may contribute to the diagnosis of invasive aspergillosis, 
but the routine use of antigen detection has been hampered by 
a lack of sensitivity (3,11). Recently, a sandwich enzyme-linked 
immunosorbent assay (ELISA) was developed by Stynen et al.
(7). That assay can detect low levels of circulating galactoman­
nan in serum from patients with invasive aspergillosis. The 
sandwich ELISA uses the rat monoclonal antibody EB-A2 
which recognizes the (l-*5)-p-i>galactofuranoside side chains 
of the Aspergillus galactomannan (6). The sensitivity of this 
sandwich ELISA was 90 to 100%, and for some patients cir­
culating galactomannan was detected in the serum even before 
clinical signs and symptoms suggestive of Aspergillus infection 
became apparent (5, 7-9). A drawback, however, is that up to 
8% false-positive reactions were obtained (7-9), which may be 
due to cross-reactivity with unidentified serum components
(8). Although single false-positive reactions can be overcome 
by testing a series of serum samples (9), persistent positive 
ELISA results for patients without invasive aspergillosis have 
been reported (5, 8). False-positive reactions were found to 
occur, especially within 30 days after bone marrow transplan­
tation (8) and within 10 days after the administration of cyto­
toxic therapy to patients with hematologic malignancies (8a). 
During this period patients are often profoundly granulocyto­
penic and at high risk for both fungal and bacterial infections,
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including invasive aspergillosis. Therefore, false-positive ELISA 
reactions may be due to the presence in the serum of antigens 
from pathogens other than Aspergillus which cross-react with 
the EB-A2 monoclonal antibody, In the present study, we 
examined this possibility by analyzing by sandwich ELISA 
exoantigens from fungi and bacteria cultured from clinical 
specimens. Furthermore, serum samples from hematologic pa­
tients who were bacteremic on the day that the serum sample 
was obtained were retrospectively tested by sandwich ELISA.
The cross-reactivity of the sandwich ELISA was tested with 
exoantigens from 29 different fungi which had been cultured 
from clinical specimens (Table 1). Each fungus, which had 
been stored at -80°C, was plated onto Sabouraud dextrose 
(2%) agar and incubated at 30°C for 48 h. One loop of biomass 
was inoculated into a liquid Sabouraud medium and allowed to 
grow for 48 h (fast-growing yeasts) or 96 h (other fungi) at 30°C 
on a rotary shaker at 20 rpm. After 48 or 96 h of incubation, the 
cultures were inspected for growth and were centrifuged at 
2,000 X g for 5 min. The supernatants were filtered through a 
0.4-5-[xm-pore-size filter (Millipore S.A., Molsheim, France). 
Tenfold dilutions ranging from 1:1,000 to 1:1,000,000 were 
made in distilled water and were tested by the sandwich 
ELISA. Furthermore, 40 serum samples from febrile neutro­
penic patients from whom blood for culture had been obtained 
on the same day and whose blood had become positive on 
incubation were tested by the sandwich ELISA, These cultures 
yielded Staphylococcus epidermidis (n = 5), Staphylococcus au­
reus (n = 1), Streptococcus sanguis (n = 3), Streptococcus mitis 
(n =  5), Streptococcus oralis (n = 2), Streptococcus pneumoniae 
(n — 1), Enterococcus faecalis (n ~ 3), Micrococcus sp. (n = 1), 
Coiynebacterium jeikeium (n =  6), Pseudomonas aemginosa 
(n = 4 ) ,  Pseudomonas cepacia (ji = 1), Escherichia coli (n = 4), 
Enterobacter cloacae (n = 2), Achromobacter xylosoxidans (n = 
1), and the yeast Candida albicans (n -  1). The bacteria and 
yeast cultured from the blood were thought to be primarily 
responsible for the febrile episode of the patient. Since con­
current infections are common in these patients, the clinical 
records of each patient were reviewed for the presence of other 
infections, especially invasive aspergillosis. Furthermore, if a 
serum sample tested positive by the sandwich ELISA, the mi­
crobiological records of the patients were reviewed for test 
results for additional serum samples which had been collected 
within 7 days before or after the positive serum sample was 
obtained and analyzed by sandwich ELISA. The bacterial iso-
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TABLE L Reactivity of the sandwich ELISA with exoantigens in a 






Reactivity compared with 
that of Aspergillus 
fumiga tus“
Aspergillus fumigatus 5.4 100
Aspergillus flavus 5.8 107
Aspergillus niger 6.4 119
Aspergillus terreus 6.6 122
Paecilo11 lyces va t ioti i 5.7 106
PenidUiimi clvysogenum 6.9 128
Penicillium digitatiun 5.8 107
Altemaria species 2.1 39
Rhodotonda rubra 0.7 13
Fusarium sohmi 0.6 11
Fi isariwn oxysporum 0.3 6
Trichopl\yioii mentagivphytes 0.4 7
Trichophyton ntbrum 0.5 9
Rhizopus oiyzae 0.4 7
Absidia cotymbifera 0.4 7
Scopulariopsis brevicaulis 0.4 7
Exophilia specics 0.4 7
Cladosporium  species 0.5 9
Pseudallescheria boydii 0.4 7
Trich oderm a viride 0.4 7
Acremonium  species 0.4 7
Candida albicans 0.3 6
Candida gin bra ta 0.3 6
Candida krusei 0.3 6
Cat idida p  amps Hosts 0.3 6
Candida tropicalis 0.3 6
Geotriclmm candidun i 0.4 7
Saccharonlyces cerevisiae 0.4 7
Ciyptococcus neoformans 0.3 6
“ The reactivity for Aspergillus fumigants is set at 100.
lates were subcultureel on sheep blood agar plates. From each 
isolate dilutions with turbidities equivalent to that of a 0.5 
McFarland standard were made and tested by the sandwich 
ELISA. The sandwich ELISA was performed exactly as de­
scribed previously (7). Briefly, 300 |xl of each sample was mixed 
with 100 jjlI of treatment solution, and the mixture was subse­
quently boiled for 3 min. After centrifugation, the supernatant 
was used for further testing. Fifty microliters of conjugate was 
added to each well of an antigalactomannan immunoglobulin 
M-coatcd microtiter plate (Sanofi Diagnostics Pasteur, Mar- 
nes-la-Coquette, France); this was followed by addition of 50 
pi of the treated sample. Each plate contained a positive con­
trol (5 ng of galactomannan per ml), a weakly positive control 
(1 ng/ml), and a negative control (0 ng/ml). After 90 min of 
incubation at 37°C, the plates were washed, 100 jxl of substrate 
buffer containing orf/io-phenylenediamine hydrochloride was 
added to each well, and the mixture was incubated for 30 min 
at room temperature in the darkness. Ail assays were per­
formed in duplicate. The galactomannan concentration in the 
eulture supernatants was deduced from the optical density 
measured at 450 nm and were correlated to a standard curve. 
The ratio between the optical density of the serum sample and 
that of the control serum spiked with 1 ng of galactomannan 
per ml was calculated for each serum sample, and a ratio larger 
than 1.5 was considered positive, which is recommended by the 
manufacturer.
The sandwich ELISA may be used to detect circulating As­
pergillus galactomannan in the serum of neutropenic patients
TABLE 2. Reactivity of the sandwich ELISA with serum samples 
obta ined  f rom  febrile neutropenic patients  from whom blood
samples for  culture obtained on the same day were positive for the
indicated microorganisms
. . No. of scrum samples
Microorganism culturcd positive/no. of
from the blood ^
Gram-posi t ive organisms
Staphylococcus epidermidis........................................................2/5







Coiyneba ctcrium jeikeium ..........................................................  1/6
Gram-negat ive  organisms
Pseudomonas aeruginosa............................................................  1/4
Pseudomonas cepacia..................................................................0/1




with fever. However, infections with other fungal or bacterial 
pathogens may cause a positive ELISA reaction by the pro­
duction and release into body fluids of exoantigens which 
cross-react with the EB-A2 rat monoclonal antibody. In pre­
paring the exoantigens of the 29 fungi tested in the present 
study, we tried to mimic the clinical situation as much as 
possible by culturing the fungi at 30°C and by analyzing only 
the culture supernatant without homogenizing each fungus 
itself. The reactivity of the sandwich ELISA with exoantigens 
prepared from various fungi is presented in Table 1. As ex­
pected, the exoantigens of Aspergillus fumigatus, Aspergillus 
flavus, Aspergillus niger, and Aspergillus (erreus showed strong 
reactivities, ranging from 5.4 to 6.6 ng/ml at the 1:1,000 dilu­
tion. Penicillium clvysogenum and PeniciUium dígita turn 
showed similar reactivities in the ELISA. The cross-reactivity 
of EB-A2 observed with exoantigens from P. chiysogenum and 
P1 dígito turn corresponded to that indicated in earlier reports 
(2, 6). Although these fungi are rarely involved in human 
disease, they may cause false-positive ELISA reactions as a 
result of their contamination of clinical specimens (2). We also 
found that the EB-A2 monoclonal antibody cross-reacted with 
exoantigens of Paecilomyces variotii, which is a fungus highly 
related to Aspergillus organisms (10). In contrast to the findings 
of Kappe and Schulze-Berge (2), we were unable to find cross­
reactivity with antigens from Trichophyton ntbnim, Trichophy­
ton mentagrophytes, Fusarium oxysponun, Rhodotonda rubra, 
Exophiala species, and Cladosporium species, which may be 
due to differences in the preparation of the exoantigens. Fi­
nally, an Alternaría species was also reactive, but the reactivity 
was significantly lower than those of the various Aspergillus 
species.
The reactivities of the serum samples from 40 febrile neu­
tropenic and bacteremic or fungemic patients by the sandwich 
ELISA are presented in Table 2. Eight serum samples (20%) 
were reactive by the ELISA, but positive ELISA reactions did 
not correspond with a specific microorganism cultured from 
the blood. Two patients were suspected of having invasive
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ELISA reactivities of sequential serum samples 
collected between 7 days before and 7 days 
after the positive sample was obtained47
1 S. epidennidis Unlikely 2.5 2.1 0,7, 0.6, 2.5, 1.0, 1.4
0 S. epidennidis Unlikely 2.9 2.3 0.7, 2.9, 2.9, 1,9, 0.5, 0.5
3 E. faecal is Possible 2.4 1.6 2.2, 2.5, 2.4, 1.8, 2.5
4 E. faecalis Unlikely 2.2 2.2 0.8, 0.8, 2.2
5 C. jeikeium Unlikely 1.8 (0,9yl 2.1 (0.8) 0.2, 0.2, 1.8, 0.8, 1.2
6 P. aeruginosa Unlikely 3.7 3.9 1.1, 3.7, 2.0
7 E. coli Unlikely 1.8 1.5 0,4, 1.8, 0.4, 1.3
8 C. albicans Proven 3.3 3.5 0.4, 1.0, 3.3, 5.8
" Unlikely infection; no clinical, radiological or microbiological evidence of invasive aspergillosis; possible infection, clinical and radiological evidence of invasive 
aspergillosis, but negative culture results; proven infection, histopathological evidence of tissue invasion by hyphac and tissue culture yielding Aspetgillus species.
h The values represent a ratio calculated by dividing the optical density of the serum sample by that of the control serum spiked with 1 ng of galactomannan per ml, 
Ratios greater than 1.5 were considered to indicate a positive result.
‘ Boldface values represent the reactivities of the scrum samples that were obtained during the episode of bactcremia or fungemia. 
ll Values in parentheses indicate the reactivities of a second scrum sample that was obtained on the same day.
aspergillosis (patients 3 and 8, Table 3), and when the results 
for these samples were not taken into account, the false-posi- 
tivity rate was 15%, which is higher than the 8% reported 
previously (7, 9). The reactivities of the positive serum samples 
by the sandwich ELISA were found to be reproducible (Table
3) and did not result from the presence of bacteria or C. 
albicans in the blood since the cross-reactivity of EB-A2 with 
the cultured bacteria and yeast was not observed (data not 
shown). To examine if the reactivity was present in a single 
sample or in sequential samples, additional samples were se­
lected from the eight patients. Twenty-seven scrum samples 
which had been collected between 7 days before and 7 days 
after the positive serum sample was obtained were retrospec­
tively tested by the sandwich ELISA (Table 3). Reactivity was 
found for a single serum sample from each of four patients 
(patients 1, 4, 5, and 7) and repeated reactivity was present for 
serum samples from the remaining four patients (patients 2, 3, 
6, and 8) including those suspected of having invasive aspergil­
losis. A second serum sample was obtained from patient 5 on 
the day that he was bacteremic, and this sample showed no 
reactivity by the ELISA (Table 3). These results confirm ear­
lier reports that ELISA reactivity may occur both with single 
(7, 9) and sequential (5, 8) serum samples from patients with­
out evidence of invasive aspergillosis, Consequently, earlier 
recommendations to determine the reactivity with additional 
serum samples (7, 9) may prove useful for some patients, but it 
will not detect those with false-positive ELISA results with 
sequential samples. Until the reason for the false-positive re­
activity is found, it will be very difficult to distinguish the latter 
group from those with true antigenemia. However, the course 
of the ELISA reactivity may help to interpret the ELISA re­
sults correctly. Provided that the serum samples are collected 
regularly, e.g., not less than twice weekly, a sudden rise in the 
ELISA reactivity would suggest false-positive reactivity (pa­
tients 4 and 7), while a more protracted rise would indicate the 
presence of an Aspergillus infection (patient 8). However, the 
differences in the course of the ELISA reactivity are subtle, 
and therefore, we recommend that a positive ELISA result 
should be confirmed by testing additional serum samples by 
the sandwich ELISA and, if they are found to be positive, 
obtain evidence of invasive aspergillosis by another diagnostic 
test or procedure such as early high-resolution computed to­
mography (12).
The present study suggests that the exoantigens of the tested 
fungi and bacteria are not responsible for the false-positive 
reactions by the sandwich ELISA. Other factors may therefore 
be of importance. This patient population frequently receive 
transfusions with blood products, but false-positive reactions 
with antiglobulin serum and blood products has not been 
found and rules out this factor (8). False-positive antigenemia 
may be induced by the agents used for immunosuppressive 
therapy. Indeed, false-positive reactions by the Pastorex A s­
pergillus latex agglutination test, which employs the same 
monoclonal antibody used by the sandwich ELISA, have been 
reported with the urine of rats treated with cyclophosphamide 
(1), and this factor needs to be studied in more detail. Also, 
severe mucositis, which is present in both bone marrow trans­
plant recipients and patients receiving cytotoxic chemotherapy 
may play a role by enhancing the resorption of galactomannan 
or cross-reacting factors from the intestine,
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